We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Genome-Wide Association Leads to Heart Failure Risk Loci

By LabMedica International staff writers
Posted on 23 Jan 2020
Heart failure (HF) affects more than 30 million individuals worldwide and its prevalence is rising. More...
HF-associated morbidity and mortality remain high despite therapeutic advances, with 5-year survival averaging around 50%.

HF is a clinical syndrome defined by fluid congestion and exercise intolerance due to cardiac dysfunction. HF results typically from myocardial disease with impairment of left ventricular (LV) function manifesting with either reduced or preserved ejection fraction.

An international team of scientists led by the University College London (London, UK) collected data for almost one million individuals with or without heart failure, focusing in on 12 variants at 11 loci that coincided with the heart failure cases. They also attempted to tease out variants associated with underlying heart failure causes, from atrial fibrillation to coronary artery disease, which highlighted risk loci in and around genes from pathways contributing to cardiac development and other processes.

For the meta-analysis, the team considered genotyping profiles generated with high-density arrays and imputation in 47,309 individuals of European descent with heart failure and 930,014 without, enrolled through more than two dozen prior analyses by members of the "Heart Failure Molecular Epidemiology for Therapeutic Targets" consortium. Based on data spanning more than 8.2 million common and less frequent variants, the team incorporated tissue-specific gene expression and other data to take a look at the potential regulatory and functional effects of these apparent risk SNPs, along with their pleiotropic effects.

The team reported that functional analysis of non-coronary artery disease (CAD)-associated loci implicate genes involved in cardiac development (MYOZ1, SYNPO2L), protein homoeostasis (BAG3), and cellular senescence (CDKN1A). Mendelian randomization analysis supports causal roles for several HF risk factors, and demonstrates CAD-independent effects for atrial fibrillation, body mass index, and hypertension.

The authors concluded that they had identified a modest number of genetic associations for HF compared to other cardiovascular disease genome-wide association (GWAS) of comparable sample size, such as for atrial fibrillation (AF), suggesting that an important component of HF heritability may be more attributable to specific disease subtypes than components of a final common pathway. The study was published on January 9, 2020 in the journal Nature Communications.

Related Links:
University College London


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Automated Urinalysis Solution
UN-9000
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.